Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2-oxoglutarate + O2 + ascorbate
succinate + dehydroascorbate + CO2 + H2O
-
-
-
?
DALTLLAPAAGDTIISLFG + 2-oxoglutarate + O2
DALTLLA-((4R)-4-hydroxy-L-proline)-AAGDTIISLFG + succinate + CO2
-
-
-
?
DLDLEMLAPAIPMDDDFQL + 2-oxoglutarate + O2
DLDLEMLA-((4R)-4-hydroxy-L-proline)-AIPMDDDFQL + succinate + CO2
-
-
-
?
DLDLEMLAPGIPMDDDFQL + 2-oxoglutarate + O2
DLDLEMLAPGIPMDDDFQL trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMD + 2-oxoglutarate + O2
DLDLEMLAPYIPMD trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMDD + 2-oxoglutarate + O2
DLDLEMLAPYIPMDD trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMDDDF + 2-oxoglutarate + O2
DLDLEMLAPYIPMDDDF trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMDDDFQL + 2-oxoglutarate + O2
DLDLEMLAPYIPMDDDFQL trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMDDDFQLRSFDQ + 2-oxoglutarate + O2
DLDLEMLAPYIPMDDDFQLRSFDQ trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLEMLAPYIPMDDDFQL + 2-oxoglutarate + O2
DLEMLA-((4R)-4-hydroxy-L-proline)-YIPMDDDFQL + succinate + CO2
-
-
-
?
EMLAPYIPMDDDFQL + 2-oxoglutarate + O2
EMLAPYIPMDDDFQL trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
hypoxia-inducible factor alpha L-proline + 2-oxoglutarate + O2
hypoxia-inducible factor alpha trans-4-hydroxy-L-proline + succinate + CO2
isoform EGLN1 acts upon both the N-and the C-terminal oxygen-dependent degradation domain to target hypoxia-inducible factor alpha for proteasomal degradation
-
-
?
hypoxia-inducible factor L-proline + 2-oxoglutarate + O2
hypoxia inducible factor trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
(2S,4S)-4-fluoroproline + 2-oxoglutarate + O2
(2S)-4-oxoproline + fluoride
-
development and evaluation of an assay method that continuously and directly detects turnover of the proline-containing substrate. The assay is based on (2S,4S)-4-fluoroproline, a proline analogue that is transformed into (2S)-4-oxoproline and inorganic fluoride by P4H using a fluoride ion-selective electrode for detection
-
-
?
(GPP)10 + 2-oxoglutarate + O2
?
-
-
-
-
?
(L-Pro-L-Pro-Gly)10 + 2-oxoglutarate + O2
(L-Pro-L-Pro-Gly)10-trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
r
(L-Pro-L-Pro-Gly)2 + 2-oxoglutarate + O2
(L-Pro-L-Pro-Gly)2-trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
r
(L-Pro-L-Pro-Gly)5 + 2-oxoglutarate + O2
(L-Pro-L-Pro-Gly)5-trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
r
(Pro-Pro-Gly)10 + 2-oxoglutarate + O2
? + succinate + CO2
(Pro-Pro-Gly)10 + 2-oxoglutarate + O2
trans-4-hydroxy-L-proline (Pro-Pro-Gly)10 + succinate + CO2
-
-
-
?
(Pro-Pro-Gly)10 L-proline + 2-oxoglutarate + O2
(Pro-Pro-Gly)10 trans-4-hydroxy-L-proline + succinate + CO2
(Pro-Pro-Gly)2 L-proline + 2-oxoglutarate + O2
(Pro-Pro-Gly)2 trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
2-oxoglutarate + O2 + ascorbate
succinate + dehydroascorbate + CO2 + H2O
Argonaute 2 + 2-oxoglutarate + O2
4-hydroxyproline-Argonaute 2 + succinate + CO2
-
regulation of Ago 2 protein activity via substrate protein stability involving Ago Pro700 residue, the Ago protein mutant P700A is destabilized, overview
-
-
?
Argonaute protein + 2-oxoglutarate + O2
4-hydroxyproline-Argonaute protein + succinate + CO2
-
i.e. GERp95 or Golgi endoplasmic reticulum protein 95 kDa. Recombinant substrate proteins expressed in HeLa S3 cells. Ago2 is a cytoplasmically exposed, peripheral membrane protein that exists in a protease-resistant complex. Hydroxylation of Pro700, which is important for Ago2 stability, but not of Ago1 or Ago3 stability, identification by mass spectrometric analysis. In vitro, both Ago2 and Ago4 seem to be more efficiently hydroxylated than Ago1 and Ago3 by recombinant human isozyme C-P4H(I)
-
-
?
biotin-Ahx-DLDLEALAP564YIPADDDFQL + 2-oxoglutarate + O2
?
-
19mer HIF peptide not containing cysteine is used, in order to rule out an involvement of the cysteine nitrosylation
-
-
?
DALTLLAPAAGDTIISLDYG + 2-oxoglutarate + O2
?
-
NODD peptide derived from native HIF-1alpha395-414
-
-
?
DALTLLAPAAGDTIISLFG + 2-oxoglutarate + O2
DALTLLA-((4R)-4-hydroxy-L-proline)-AAGDTIISLFG + succinate + CO2
-
-
-
?
dansyl-Gly-Phe-Pro-Gly-OEt + 2-oxoglutarate + O2
dansyl-Gly-Phe-4-hydroxy-L-Pro-Gly-OEt + succinate + CO2
-
-
-
-
?
dansyl-Gly-Phe-Pro-Gly-OEt + 2-oxoglutarate + O2
dansyl-Gly-Phe-trans-4-hydroxy-L-proline-Gly-OEt + succinate + CO2
-
-
-
-
?
DLDLEALAPYIPADDDFQL + 2-oxoglutarate + O2
?
-
CODD peptide derived from native HIF-1alpha556-574. PHD2 preferred CODD by 20fold over NODD
-
-
?
DLDLEMLAPAIPMDDDFQL + 2-oxoglutarate + O2
DLDLEMLA-((4R)-4-hydroxy-L-proline)-AIPMDDDFQL + succinate + CO2
-
-
-
?
DLDLEMLAPAIPMDDDFQLRSFDQ + 2-oxoglutarate + O2
DLDLEMLAPAIPMDDDFQLRSFDQ trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPGIPMDDDFQL + 2-oxoglutarate + O2
DLDLEMLAPGIPMDDDFQL trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMD + 2-oxoglutarate + O2
DLDLEMLAPYIPMD trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMDD + 2-oxoglutarate + O2
DLDLEMLAPYIPMDD trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMDDDF + 2-oxoglutarate + O2
DLDLEMLAPYIPMDDDF trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMDDDFQL + 2-oxoglutarate + O2
DLDLEMLAPYIPMDDDFQL trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLDLEMLAPYIPMDDDFQLRSFDQ + 2-oxoglutarate + O2
DLDLEMLAPYIPMDDDFQLRSFDQ trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
DLEMLAPYIPMDDDFQL + 2-oxoglutarate + O2
DLEMLA-((4R)-4-hydroxy-L-proline)-YIPMDDDFQL + succinate + CO2
-
-
-
?
EMLAPYIPMDDDFQL + 2-oxoglutarate + O2
EMLAPYIPMDDDFQL trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
Gly-Val-Pro-Gly-Val + 2-oxoglutarate + O2
Gly-Val-4-hydroxyproline-Gly-Val + succinate + CO2
-
-
?
hypoxia-induced factor alpha oxygen-dependent degradation domain L-proline + 2-oxoglutarate + O2
hypoxia-induced factor alpha oxygen-dependent degradation domain L-4-hydroxyproline + succinate + CO2
-
-
in vitro hydroxylation of two proline residues, with preference for C-terminal proline
-
?
hypoxia-inducible factor alpha L-proline + 2-oxoglutarate + O2
hypoxia-inducible factor alpha trans-4-hydroxy-L-proline + succinate + CO2
hypoxia-inducible factor L-proline + 2-oxoglutarate + O2
hypoxia inducible factor trans-4-hydroxy-L-proline + succinate + CO2
hypoxia-inducible factor L-proline + 2-oxoglutarate + O2
hypoxia-inducible factor trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
?
hypoxia-inducible transcription factor + 2-oxoglutarate + O2
hypoxia-inducible transcription factor trans-4-hydroxy-L-proline + succinate + CO2
L-Pro-L-Pro-Gly + 2-oxoglutarate + O2
L-Pro-L-Pro-Gly-trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
r
LAPYIPMDDDFQL + 2-oxoglutarate + O2
LAPYIPMDDDFQL trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
PEG-Gly-Tyr-4-fluoroproline-GlyOEt + 2-oxoglutarate + O2
?
-
-
-
-
?
poly(ethylene glycol)-Gly-L-Tyr-(2S)-4-thiaproline-Gly-OCH2CH2OH + 2-oxoglutarate + O2
poly(ethylene glycol)-Gly-L-Tyr-L-(2S,4R)-thiaoxoproline-Gly-OCH2CH2OH + ? + CO2
-
6% of the activity with L-prolyl peptide substrate
-
-
?
poly(ethylene glycol)-Gly-L-Tyr-L-(2S,4S)-4-fluoroproline-Gly-OCH2CH2OH + 2-oxoglutarate + O2
poly(ethylene glycol)-Gly-L-Tyr-L-(2S)-4-oxoproline-Gly-OCH2CH2OH + ? + CO2
-
26% of the activity with L-prolyl peptide substrate
-
-
?
poly(ethylene glycol)-Gly-L-Tyr-L-Pro-Gly-OCH2CH2OH + 2-oxoglutarate + O2
poly(ethylene glycol)-Gly-L-Tyr-L-(2S,4R)-4-hydroxy-Pro-Gly-OCH2CH2OH + succinate + CO2
-
-
-
-
?
poly(L-Pro) + 2-oxoglutarate + O2
poly(4-hydroxyproline) + succinate + CO2
MW: 7000 and 44000
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-(2S,4R)-4-hydroxy-L-proline + succinate + CO2
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
proline containing peptide + 2-oxoglutarate + O2
4-hydroxyproline containing peptide + succinate + CO2
protocollagen + 2-oxoglutarate + O2
4-hydroxyproline containing protocollagen + succinate + CO2
protocollagen type I L-proline+ 2-oxoglutarate + O2
protocollagen type I-trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
r
additional information
?
-
(Pro-Pro-Gly)10 + 2-oxoglutarate + O2
? + succinate + CO2
-
-
-
-
?
(Pro-Pro-Gly)10 + 2-oxoglutarate + O2
? + succinate + CO2
-
-
-
?
(Pro-Pro-Gly)10 L-proline + 2-oxoglutarate + O2
(Pro-Pro-Gly)10 trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
?
(Pro-Pro-Gly)10 L-proline + 2-oxoglutarate + O2
(Pro-Pro-Gly)10 trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
-
n: 1,5,10
n: 1,5,10
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
-
n: 1,5,10
n: 1,5,10
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
-
n: 1,5,10
n: 1,5,10
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
-
n: 1,5,10
n: 1,5,10
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
-
n: 1,5,10
n: 1,5,10
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
-
n: 1,5,10
n: 1,5,10
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
-
n: 1,5,10
n: 1,5,10
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
-
n: 1,5,10
n: 1,5,10
?
(Pro-Pro-Gly)n + 2-oxoglutarate + O2
(Pro-4-hydroxy-Pro-Gly)n + succinate + CO2
n: 1,5,10
n: 1,5,10
?
2-oxoglutarate + O2 + ascorbate
succinate + dehydroascorbate + CO2 + H2O
-
-
-
?
2-oxoglutarate + O2 + ascorbate
succinate + dehydroascorbate + CO2 + H2O
-
-
-
?
2-oxoglutarate + O2 + ascorbate
succinate + dehydroascorbate + CO2 + H2O
-
-
-
?
hypoxia-inducible factor alpha L-proline + 2-oxoglutarate + O2
hypoxia-inducible factor alpha trans-4-hydroxy-L-proline + succinate + CO2
isoform EGLN2 acts upon both the N-and the C-terminal oxygen-dependent degradation domain to target hypoxia-inducible factor alpha for proteasomal degradation
-
-
?
hypoxia-inducible factor alpha L-proline + 2-oxoglutarate + O2
hypoxia-inducible factor alpha trans-4-hydroxy-L-proline + succinate + CO2
isoform EGLN3 acts on the N-terminal oxygen-dependent degradation domain
-
-
?
hypoxia-inducible factor L-proline + 2-oxoglutarate + O2
hypoxia inducible factor trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
hypoxia-inducible factor L-proline + 2-oxoglutarate + O2
hypoxia inducible factor trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
?
hypoxia-inducible factor L-proline + 2-oxoglutarate + O2
hypoxia inducible factor trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
hypoxia-inducible transcription factor + 2-oxoglutarate + O2
hypoxia-inducible transcription factor trans-4-hydroxy-L-proline + succinate + CO2
-
i.e. HIF, an alphabetaheterodimer, in which the stability of the alpha-subunti is regulated in an oxygen-dependent manner. Hydroxylation of one or two critical proline residues in the oxygen-dependent degradation domain leads to proteasomal degradation of the protein under normic conditions, while under hypoxic conditions the oxygen-requiring hydroxylation is inhibited and HIF-alpha escapes degradation and dimerizes with HIF-beta, overview
-
-
?
hypoxia-inducible transcription factor + 2-oxoglutarate + O2
hypoxia-inducible transcription factor trans-4-hydroxy-L-proline + succinate + CO2
-
i.e. HIF, oxygen-dependent hydroxylation of proline residues in the alpha subunit of hypoxia-inducible transcription factor is central to the hypoxic response in animals. Prolyl hydroxylation of HIFalpha increases its binding to the von Hippel-Lindau protein, thus signaling for degradation via the ubiquitin-proteasome system
-
-
?
hypoxia-inducible transcription factor + 2-oxoglutarate + O2
hypoxia-inducible transcription factor trans-4-hydroxy-L-proline + succinate + CO2
-
i.e. HIF
-
-
?
hypoxia-inducible transcription factor + 2-oxoglutarate + O2
hypoxia-inducible transcription factor trans-4-hydroxy-L-proline + succinate + CO2
-
i.e. HIF, the substrate prolyl-residue is bound in a specific conformation and that a significant structural change involving a mobile loop likely occurs concomitant with HIFalpha binding. PHD catalysis involves the mobile region that isolates the hydroxylation site and stabilizes the PHD2-Fe2+-2OG complex. The hydroxylation sites of both NODD and CODD of HIFalpha occur within a conserved LXXLAP motif. In the tPHD2-CODD structure, Leu559CODD, Leu562CODD, and Ala563CODD of the LXXLAP motif form part of the CODD310-helix and make hydrophobic interactions with tPHD2
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-(2S,4R)-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-(2S,4R)-4-hydroxy-L-proline + succinate + CO2
-
prolyl 4-hydroxylase is a nonheme iron dioxygenase that catalyzes the posttranslational hydroxylation of (2S)-Pro residues in protocollagen strands
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
-
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
key enzyme in collagen biosynthesis, catalyzes the conversion of selected prolyl residues to trans-hydroxyproline in nascent or completed pro-alpha chains of procollagen
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
the biological substrate for the enzyme is a proline residue in an appropriate sequence of a growing or newly synthesized polypeptide chain
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
acts on -Xaa-Pro-Gly triplets in collagen
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
P4H catalyzes the post-translational hydroxylation of proline residues in protocollagen strands, stabilizing the ensuing triple helix
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
-
high stringency for the iron-binding residues in the P4H active site, structure-function relationship, overview
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
PxGP (where x is not a proline) is the common motif of proline-rich peptide sequences that bind with high affinity to the enzyme (PSB-II)
-
-
?
procollagen L-proline + 2-oxoglutarate + O2
procollagen trans-4-hydroxy-L-proline + succinate + CO2
the enzyme preferentially recognizes the cis conformation of the prolyl peptide bond
-
-
?
proline containing peptide + 2-oxoglutarate + O2
4-hydroxyproline containing peptide + succinate + CO2
-
-
-
?
proline containing peptide + 2-oxoglutarate + O2
4-hydroxyproline containing peptide + succinate + CO2
-
no hydroxylation of free proline, minimum sequence required X-Pro-Gly, best substrates are those where Pro precedes Gly, which can be substituted by Ala or beta-alanine. The amino acid preceding Pro can be Pro, Ala, Leu, Arg, Val, Glu, but not Gly or Ser. Additionally the sequence, the conformation and the peptide chain length influence the rate of hydroxylation
-
?
proline containing peptide + 2-oxoglutarate + O2
4-hydroxyproline containing peptide + succinate + CO2
-
the presence of 2-oxoglutarate is an absolute and highly specific requirement, the formation of 4-hydroxyproline is accompanied by a stoichiometric decarboxylation of 2-oxoglutarate, the oxygen of the hydroxyl group is derived from molecular oxygen, the other atom of the O2 molecule being incorporated into the succinate, the activated form of oxygen is probably superoxide
-
?
proline containing peptide + 2-oxoglutarate + O2
4-hydroxyproline containing peptide + succinate + CO2
-
the presence of 2-oxoglutarate is an absolute and highly specific requirement, the formation of 4-hydroxyproline is accompanied by a stoichiometric decarboxylation of 2-oxoglutarate, the oxygen of the hydroxyl group is derived from molecular oxygen, the other atom of the O2 molecule being incorporated into the succinate, the activated form of oxygen is probably superoxide
-
-
?
protocollagen + 2-oxoglutarate + O2
4-hydroxyproline containing protocollagen + succinate + CO2
-
-
-
?
protocollagen + 2-oxoglutarate + O2
4-hydroxyproline containing protocollagen + succinate + CO2
-
-
?
additional information
?
-
-
no substrate: prolines in recombinant type I procollagen chains
-
-
?
additional information
?
-
-
HIF prolyl hydroxylases are related to the collagen prolyl hydroxylases, but form unusually stable complexes with their Fe2+ cofactor and 2-oxoglutarate cosubstrate
-
-
?
additional information
?
-
-
C-P4H catalyses proline hydroxylation of collagens in the X-Pro-Gly (X-P-G) triplets
-
-
?
additional information
?
-
-
the carboxy group of 2-oxoglutarate is bound by Lys493 in subunit alphaI, substrate and ligand binding structures, overview
-
-
?
additional information
?
-
-
the heat shock protein 90 (HSP90) co-chaperones p23 and FKBP38 interact via a conserved Pro-Xaa-Leu-Glu motif in these proteins with the N-terminal Myeloid Nervy and DEAF-1 (MYND)-type zinc finger of PHD2
-
-
?
additional information
?
-
prolyl-4-hydroxylase (P4H) is a non-heme iron hydroxylase that regio- and stereospecifically hydroxylates proline residues in a peptide chain into R-4-hydroxyproline. In P4H, a strong aliphatic C-H bond is activated, while thermodynamically much weaker aliphatic C-H groups, that is, at the C3 and C5 positions, are untouched
-
-
?
additional information
?
-
-
prolyl-4-hydroxylase (P4H) is a non-heme iron hydroxylase that regio- and stereospecifically hydroxylates proline residues in a peptide chain into R-4-hydroxyproline. In P4H, a strong aliphatic C-H bond is activated, while thermodynamically much weaker aliphatic C-H groups, that is, at the C3 and C5 positions, are untouched
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acute Kidney Injury
Role of Endothelial Prolyl-4-Hydroxylase Domain Protein/Hypoxia-Inducible Factor Axis in Acute Kidney Injury.
Adenocarcinoma
P4HA1/HIF1? feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.
Adenocarcinoma of Lung
Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinoma.
Adenocarcinoma of Lung
Overexpression of P4HA1 Is Correlated with Poor Survival and Immune Infiltrates in Lung Adenocarcinoma.
Adenocarcinoma of Lung
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors.
Alzheimer Disease
HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease.
Anemia
1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.
Anemia
A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
Anemia
A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma.
Anemia
A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat.
Anemia
A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study.
Anemia
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Anemia
A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
Anemia
A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Anemia
An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects.
Anemia
Anemia Management in Peritoneal Dialysis: Perspectives From the Asia Pacific Region.
Anemia
Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways.
Anemia
Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
Anemia
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.
Anemia
Daprodustat: First Approval.
Anemia
Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.
Anemia
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.
Anemia
Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
Anemia
Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.
Anemia
Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Anemia
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Anemia
Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Anemia
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
Anemia
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
Anemia
Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Anemia
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Anemia
Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
Anemia
Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats.
Anemia
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Anemia
Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
Anemia
Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Anemia
Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
Anemia
Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: a systematic review and meta-analysis.
Anemia
Enarodustat to treat anemia in chronic kidney disease.
Anemia
Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
Anemia
Erythropoietin regulates metabolic response in mice via receptor expression in adipose tissue, brain and bone.
Anemia
Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
Anemia
Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
Anemia
Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
Anemia
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
Anemia
HIF prolyl hydroxylase inhibitors for anemia.
Anemia
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
Anemia
Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Anemia
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Anemia
Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
Anemia
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
Anemia
Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Anemia
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Anemia
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
Anemia
Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?
Anemia
Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Anemia
In response to "Title: Letter to the Editor in response to the article 'Efficacy and safety of HIF prolyl hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis'".
Anemia
In vivo functions of the prolyl-4-hydroxylase domain oxygen sensors: direct route to the treatment of anaemia and the protection of ischaemic tissues.
Anemia
Inhibition of firefly luciferase activity by a HIF prolyl hydroxylase inhibitor.
Anemia
Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Anemia
Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Anemia
Iron metabolism and management: focus on chronic kidney disease.
Anemia
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Anemia
Iron Therapy in Chronic Kidney Disease: Days of Future Past.
Anemia
JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
Anemia
Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis.
Anemia
Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Anemia
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Anemia
Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.
Anemia
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Anemia
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Anemia
Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Anemia
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective HIF prolyl hydroxylase (PHD) inhibitor.
Anemia
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Anemia
Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD.
Anemia
Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
Anemia
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Anemia
Pyrazolo[4,3-d]pyrimidine Derivatives as a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor for the Treatment of Anemia.
Anemia
Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
Anemia
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
Anemia
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
Anemia
Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis.
Anemia
Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.
Anemia
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.
Anemia
The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia.
Anemia
The problem with transferrin saturation as an indicator of iron 'sufficiency' in chronic kidney disease.
Anemia
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Anemia
Treatment of Diabetic Kidney Disease: Current and Future.
Anemia
Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
Anemia
Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
Anemia
Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.
Anemia
Zinc Inhibits HIF-Prolyl Hydroxylase Inhibitor-Aggravated VSMC Calcification Induced by High Phosphate.
Anemia
[Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
Anemia
[Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Anemia, Refractory
Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor.
Anthrax
Crystal structure of prolyl 4-hydroxylase from Bacillus anthracis.
Arteriosclerosis
Aortic proline hydroxylase in hypoxia induced arteriosclerosis in rabbits.
Arteriosclerosis
Elevation of aortic proline hydroxylase: a biochemical defect in experimental arteriosclerosis.
Arteriosclerosis
Proline hydroxylase in injury-induced arteriosclerosis.
Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Arthritis, Rheumatoid
Connective tissue metabolites in serum as markers of disease activity in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Increased protocollagen proline hydroxylase activity in synovial tissue in rheumatoid arthritis.
Arthritis, Rheumatoid
Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry.
Arthritis, Rheumatoid
Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxic responses in rheumatoid arthritis.
Ascorbic Acid Deficiency
Intracellular retention of procollagen within the endoplasmic reticulum is mediated by prolyl 4-hydroxylase.
Atherosclerosis
Adipocyte Hypoxia-Inducible Factor 2? Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism.
Atherosclerosis
Cloning of a novel prolyl 4-hydroxylase subunit expressed in the fibrous cap of human atherosclerotic plaque.
Atherosclerosis
Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Atherosclerosis
Proline hydroxylase activity and collagen content of pigeon aortas with naturally-occurring and cholesterol-aggravated atherosclerosis.
beta-Thalassemia
[Proline hydroxylase (hPH) as marker of hepatic fibrosis in beta thalassemia]
Bone Diseases, Developmental
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Bone Resorption
'Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2'.
Bone Resorption
Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2.
Bowen's Disease
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Brain Injuries
The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.
Brain Ischemia
Hydroxylase inhibition reduces synaptic transmission and protects against a glutamate-induced ischemia in the CA1 region of the rat hippocampus.
Brain Neoplasms
Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane.
Breast Neoplasms
Chemical synthesis and biochemical characterization of a biotinylated derivative of 17beta-estradiol with a long side chain covalently attached to its C-7alpha position.
Breast Neoplasms
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1? stabilization and TNBC chemoresistance.
Breast Neoplasms
Collagen Type X Alpha 1 (COL10A1) Contributes to Cell Proliferation, Migration, and Invasion by Targeting Prolyl 4-Hydroxylase Beta Polypeptide (P4HB) in Breast Cancer.
Breast Neoplasms
Deficiency of Follistatin-Like Protein 1 Accelerates the Growth of Breast Cancer Cells at Lung Metastatic Sites.
Breast Neoplasms
Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer.
Breast Neoplasms
Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis.
Breast Neoplasms
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer.
Breast Neoplasms
IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells.
Breast Neoplasms
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.
Breast Neoplasms
Mitochondrial malic enzyme 2 promotes breast cancer metastasis via stabilizing HIF-1? under hypoxia.
Breast Neoplasms
P4HA1 is a new regulator of the HIF-1 pathway in breast cancer.
Breast Neoplasms
Profiling and comparative analysis of glycoproteins in Hs578BST and Hs578T and investigation of prolyl 4-hydroxylase alpha polypeptide II expression and influence in breast cancer cells.
Breast Neoplasms
Prognostic and diagnostic roles of prolyl 4-hydroxylase subunit ? members in breast cancer.
Breast Neoplasms
Prolyl-4-hydroxylase ? subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.
Breast Neoplasms
Systemic Multi-Omics Analysis Reveals Amplified P4HA1 Gene Associated With Prognostic and Hypoxic Regulation in Breast Cancer.
Breast Neoplasms
Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
Breast Neoplasms
[Correlation of the methylation status of CpG islands in the promoter region of 10 genes with the 5-Fu chemosensitivity in 3 breast cancer cell lines]
Breast Neoplasms
[Different expression of liver-specific insulin-like growth factor I gene in breast cancer; expression with mice]
Capsule Opacification
Immunolocalization of prolyl 4-hydroxylase in rabbit lens epithelial cells.
Carcinogenesis
Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis.
Carcinogenesis
Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer.
Carcinogenesis
Downregulation of Proline Hydroxylase 2 and Upregulation of Hypoxia-Inducible Factor 1? are Associated with Endometrial Cancer Aggressiveness.
Carcinogenesis
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Carcinogenesis
Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma.
Carcinogenesis
Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.
Carcinogenesis
Suppression of glioma progression by egln3.
Carcinogenesis
Systemic Multi-Omics Analysis Reveals Amplified P4HA1 Gene Associated With Prognostic and Hypoxic Regulation in Breast Cancer.
Carcinogenesis
Tumor PHD2 expression is correlated with clinical features and prognosis of patients with HCC receiving liver resection.
Carcinoma
Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma.
Carcinoma
Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis.
Carcinoma
Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells.
Carcinoma
Desmoplastic response in scirrhous gastric carcinoma: imbalance between collagen synthesis and degradation.
Carcinoma
Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma.
Carcinoma
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Carcinoma
Expression of prolyl 4-hydroxylase beta-polypeptide in non-small cell lung cancer treated with Chinese medicines.
Carcinoma
HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma.
Carcinoma
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Carcinoma
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
Carcinoma
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Carcinoma
Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Carcinoma
Over-expression of prolyl hydroxylase-1 blocks NF-?B-mediated cyclin D1 expression and proliferation in lung carcinoma cells.
Carcinoma
Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness.
Carcinoma
Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma.
Carcinoma
P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients.
Carcinoma
Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
Carcinoma
Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker.
Carcinoma
Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Carcinoma
Prolyl-4-Hydroxylase ? Subunit 2 as a Novel Potential Biomarker for Predicting the Prognosis of Epithelial Ovarian Carcinoma.
Carcinoma, Ductal
Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Carcinoma, Hepatocellular
Aspirin targets P4HA2 through inhibiting NF-?B and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA.
Carcinoma, Hepatocellular
MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA.
Carcinoma, Hepatocellular
Molecular cloning of cDNA encoding a 55-kDa multifunctional thyroid hormone binding protein of skeletal muscle sarcoplasmic reticulum.
Carcinoma, Hepatocellular
Molecular cloning of the beta-subunit of human prolyl 4-hydroxylase. This subunit and protein disulphide isomerase are products of the same gene.
Carcinoma, Hepatocellular
Protocollagen proline hydroxylase in sera of Ugandans with hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Differential Expression of Cancer-Associated Fibroblast-Related Proteins in Ductal Carcinoma in situ According to Molecular Subtype and Stromal Histology.
Carcinoma, Intraductal, Noninfiltrating
Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Carcinoma, Non-Small-Cell Lung
Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis.
Carcinoma, Non-Small-Cell Lung
Expression of prolyl 4-hydroxylase beta-polypeptide in non-small cell lung cancer treated with Chinese medicines.
Carcinoma, Non-Small-Cell Lung
Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway.
Carcinoma, Ovarian Epithelial
Prolyl-4-Hydroxylase ? Subunit 2 as a Novel Potential Biomarker for Predicting the Prognosis of Epithelial Ovarian Carcinoma.
Carcinoma, Renal Cell
Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma.
Carcinoma, Renal Cell
Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis.
Carcinoma, Renal Cell
HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
Carcinoma, Renal Cell
Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Carcinoma, Renal Cell
Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker.
Carcinoma, Squamous Cell
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Carcinoma, Squamous Cell
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Carcinoma, Squamous Cell
Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness.
Carcinoma, Squamous Cell
Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
Cardiomegaly
Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats.
Cardiomegaly
Protocollagen proline hydroxylase activity in rat heart during experimental cardiac hypertrophy.
Cardiomyopathies
A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
Cardiomyopathies
Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.
Cardiomyopathy, Dilated
Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.
Cataract
Genome-wide analysis of methylation in giant pandas with cataract by methylation-dependent restriction-site associated DNA sequencing (MethylRAD).
Cataract
Immunolocalization of prolyl 4-hydroxylase in rabbit lens epithelial cells.
Cataract
Immunolocalization of prolyl 4-hydroxylase subunits, alpha-smooth muscle actin, and extracellular matrix components in human lens capsules with lens implants.
Cholangiocarcinoma
USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1B? via deubiquitinating EGLN3.
Chondrosarcoma
Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts.
Colitis
Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis.
Colitis
Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis.
Colitis
Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function.
Colitis, Ulcerative
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective HIF prolyl hydroxylase (PHD) inhibitor.
Colonic Neoplasms
Comprehensive Analysis of Gene Expression Profiles Identifies a P4HA1-Related Gene Panel as a Prognostic Model in Colorectal Cancer Patients.
Colorectal Neoplasms
Corrigendum to 'Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model' [Translational Oncology 13 (2020) 100754].
Colorectal Neoplasms
P4HA1 regulates human colorectal cancer cells through HIF1?-mediated Wnt signaling.
Colorectal Neoplasms
Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal cancer.
Colorectal Neoplasms
Prolyl Hydroxylase-3 Is Downregulated in Colorectal Cancer Cells and Inhibits IKKbeta, Independent of Hydroxylase Activity.
Colorectal Neoplasms
Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Contracture
Auxiliary proteins that facilitate formation of collagen-rich deposits in the posterior knee capsule in a rabbit-based joint contracture model.
Contracture
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
COVID-19
HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.
COVID-19
Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells.
Diabetic Nephropathies
The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
Endometrial Neoplasms
Downregulation of Proline Hydroxylase 2 and Upregulation of Hypoxia-Inducible Factor 1? are Associated with Endometrial Cancer Aggressiveness.
Endometriosis
An investigation of the effects of endometriosis on the proteome of human eutopic endometrium: a heterogeneous tissue with a complex disease.
Fatty Liver
Liver protocollagen proline hydroxylase in human liver diseases and experimental liver fibrosis.
Fatty Liver
Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.
Fibroma
Phenotypic characterisation of stellate and giant cells in giant cell fibroma by immunocytochemistry.
Fibrosarcoma
Regulation of collagen prolyl 4-hydroxylase and matrix metalloproteinases in fibrosarcoma cells by hypoxia.
Giant Cell Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Glaucoma
Effect of fibrostatin C, an inhibitor of prolyl 4-hydroxylase, on collagen secretion by human Tenon's capsule fibroblasts in vitro.
Glioblastoma
Defective p53 antiangiogenic signaling in glioblastoma.
Glioblastoma
Endoplasmic reticulum chaperone prolyl 4-hydroxylase, beta polypeptide (P4HB) promotes malignant phenotypes in glioma via MAPK signaling.
Glioblastoma
P4HA1 as an unfavorable prognostic marker promotes cell migration and invasion of glioblastoma via inducing EMT process under hypoxia microenvironment.
Glioblastoma
P4HA2 promotes cell proliferation and migration in glioblastoma.
Glioblastoma
P4HA2 Promotes Epithelial-to-Mesenchymal Transition and Glioma Malignancy through the Collagen-Dependent PI3K/AKT Pathway.
Glioma
Endoplasmic reticulum chaperone prolyl 4-hydroxylase, beta polypeptide (P4HB) promotes malignant phenotypes in glioma via MAPK signaling.
Glioma
Identification of P4HA1 as a prognostic biomarker for high-grade gliomas.
Glioma
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Glioma
Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane.
Glioma
P4HA1 Down-Regulation Inhibits Glioma Invasiveness by Promoting M1 Microglia Polarization.
Glioma
P4HA2 Promotes Epithelial-to-Mesenchymal Transition and Glioma Malignancy through the Collagen-Dependent PI3K/AKT Pathway.
Glioma
Potential regulation of glioma through the induction of apoptosis signaling via Egl-9 family hypoxia-inducible factor 3.
Glioma
Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Glioma
Suppression of glioma progression by egln3.
Glucose Intolerance
Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance.
Granuloma
Collagen proline hydroxylase in wound healing, granuloma formation, scurvy, and growth.
Head and Neck Neoplasms
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer.
Hemochromatosis
Familial hemochromatosis. Physiologic studies in the precirrhotic stage of the disease.
Hemorrhagic Stroke
"Branched tail" oxyquinoline inhibitors of HIF prolyl hydroxylase: Early Evaluation of Toxicity and Metabolism Using Liver-on-a-chip.
Hepatitis B
Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA.
Hepatitis B, Chronic
Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis.
Hepatitis C, Chronic
Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis.
Hepatitis, Alcoholic
Hepatic collagen proline hydroxylase activity in alcoholic hepatitis: effect of d-penicillamine.
Hepatitis, Alcoholic
Hepatic collagen proline hydroxylase activity in alcoholic liver disease.
Hodgkin Disease
Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma.
Huntington Disease
HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease.
Infections
HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.
Infections
Hypoxia Induces Permeability and Giant Cell Responses of ANDV Infected Pulmonary Endothelial Cells by Activating the mTOR-S6K Signaling Pathway.
Insulin Resistance
Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes.
Insulin Resistance
Hypoxia-inducible factor prolyl hydroxylase 1 (PHD1) deficiency promotes hepatic steatosis and liver-specific insulin resistance in mice.
Intestinal Volvulus
Characterization and expression of enzymatically active recombinant filarial prolyl 4-hydroxylase.
Iron Deficiencies
The problem with transferrin saturation as an indicator of iron 'sufficiency' in chronic kidney disease.
Iron Deficiencies
The prolyl 4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells.
Iron Overload
Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred.
Ischemic Stroke
Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke.
Joint Instability
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Keloid
Collagen biosynthesis in normal human skin, normal and hypertrophic scar and keloid.
Keloid
Collagen gene expression in keloids: analysis of collagen metabolism and type I, III, IV, and V procollagen mRNAs in keloid tissue and keloid fibroblast cultures.
Keratoconus
Increase in type I and type IV collagenolytic activity in primary cultures of keratoconus cornea.
Keratoconus
Protein-related abnormalities in keratoconus.
Keratosis, Seborrheic
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Kidney Diseases
Laser capture microdissection and multiplex-tandem PCR analysis of proximal tubular epithelial cell signaling in human kidney disease.
Kidney Diseases
Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Kidney Failure, Chronic
A Mass Balance Study of 14 C-Labeled JTZ-951 (Enarodustat), a Novel Orally Available Erythropoiesis-Stimulating Agent, in Patients With End-Stage Renal Disease on Hemodialysis.
Kidney Failure, Chronic
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Kidney Neoplasms
Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Liposarcoma
Characterization of a human cell line derived from liposarcoma tissue: is the beta subunit of prolyl 4-hydroxylase specific for a fibroblastic phenotype in culture cells?
Liver Cirrhosis
Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA.
Liver Cirrhosis
Is serum prolyl 4-hydroxylase useful as noninvasive marker of liver fibrosis in patients with biliary atresia?
Liver Cirrhosis
Liver protocollagen proline hydroxylase in human liver diseases and experimental liver fibrosis.
Liver Cirrhosis
Mechanisms by which acute phase proteins enhance development of liver fibrosis: effects on collagenase and prolyl-4-hydroxylase activity in the rat liver.
Liver Cirrhosis
New prolyl 4-hydroxylase inhibitor reduces procollagen gene expression and enzyme-altered lesions in rat liver cirrhosis.
Liver Cirrhosis
Preventive effect of malotilate on dimethylnitrosamine-induced liver fibrosis in the rat.
Liver Cirrhosis
Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation.
Liver Cirrhosis
Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis.
Liver Cirrhosis
Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor.
Liver Cirrhosis
The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet.
Liver Cirrhosis, Biliary
Fibrosis of the liver in rats induced by bile duct ligation. Effects of inhibition by prolyl 4-hydroxylase.
Liver Cirrhosis, Biliary
Hepatic collagen proline hydroxylase activity in primary biliary cirrhosis.
Liver Diseases
Liver protocollagen proline hydroxylase in human liver diseases and experimental liver fibrosis.
Liver Diseases
Studies on serum immunoreactive prolyl 4-hydroxylase in liver diseases--its elevation both in hepatocellular damage and cholestatic diseases.
Liver Diseases
Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.
Liver Diseases, Alcoholic
Hepatic collagen proline hydroxylase activity in alcoholic liver disease.
Liver Failure
Hepatic retinopathy: morphological features of retinal glial (Müller) cells accompanying hepatic failure.
Liver Neoplasms
Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA.
Liver Neoplasms
P4HB modulates epithelial-mesenchymal transition and the ?-catenin/Snail pathway influencing chemoresistance in liver cancer cells.
Lung Neoplasms
Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinoma.
Lung Neoplasms
Effects of Yiqi Chutan Tang on the Proteome in LEWIS Lung Cancer in Mice.
Lung Neoplasms
Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis.
Lung Neoplasms
Expression of prolyl 4-hydroxylase beta-polypeptide in non-small cell lung cancer treated with Chinese medicines.
Lung Neoplasms
Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway.
Lung Neoplasms
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer.
Lung Neoplasms
RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma.
Lymphatic Metastasis
Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis.
Lymphatic Metastasis
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Lymphoma
Localization of collagen modifying enzymes on fibroblastic reticular cells and follicular dendritic cells in non-neoplastic and neoplastic lymphoid tissues.
Lymphoma
Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin.
Lymphoma
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.
Lymphoma, B-Cell
Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin.
Lymphoma, B-Cell
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Lymphoma, Large B-Cell, Diffuse
Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin.
Melanoma
A reliable set of reference genes to normalize oxygen-dependent cytoglobin gene expression levels in melanoma.
Melanoma
Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma.
Melanoma
New phenotypical and ultrastructural findings in spindle cell (desmoplastic/neurotropic) melanoma.
Melanoma
Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls.
Melanoma
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.
Metabolic Diseases
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective HIF prolyl hydroxylase (PHD) inhibitor.
Mitochondrial Diseases
Multi-OMICS study of a CHCHD10 variant causing ALS demonstrates metabolic rewiring and activation of endoplasmic reticulum and mitochondrial unfolded protein responses.
Monoclonal Gammopathy of Undetermined Significance
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Multiple Myeloma
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Muscle Weakness
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Muscular Atrophy
Global alternative splicing landscape of skeletal muscle atrophy induced by hindlimb unloading.
Myocardial Infarction
Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium.
Myocardial Infarction
Chronic Inhibition of Hypoxia-Inducible Factor (HIF) Prolyl 4-Hydroxylase Improves Ventricular Performance, Remodeling and Vascularity Following Myocardial Infarction in the Rat.
Myocardial Infarction
Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.
Myocardial Infarction
Depletion of Endothelial Prolyl Hydroxylase Domain Protein 2 and 3 Promotes Cardiomyocyte Proliferation and Prevents Ventricular Failure Induced by Myocardial Infarction.
Myocardial Infarction
Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction.
Myocardial Infarction
Myocardium-targeted transplantation of PHD2 shRNA-modified bone mesenchymal stem cells through ultrasound-targeted microbubble destruction protects the heart from acute myocardial infarction.
Myocardial Infarction
Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult.
Myocardial Ischemia
Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection.
Myopia
Autosomal-dominant myopia associated to a novel P4HA2 missense variant and defective collagen hydroxylation.
Myopia
Mutations of P4HA2 encoding prolyl 4-hydroxylase 2 are associated with nonsyndromic high myopia.
Myopia
P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye.
Neoplasm Metastasis
Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate.
Neoplasm Metastasis
Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis.
Neoplasm Metastasis
Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis.
Neoplasm Metastasis
Identification of a novel glycolysis-related gene signature for predicting the prognosis of osteosarcoma patients.
Neoplasm Metastasis
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Neoplasm Metastasis
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.
Neoplasm Metastasis
LncRNA PCGEM1 enhances metastasis and gastric cancer invasion through targeting of miR-129-5p to regulate P4HA2 expression.
Neoplasm Metastasis
Metabolic Rewiring and the Characterization of Oncometabolites.
Neoplasm Metastasis
MiR-122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cells.
Neoplasm Metastasis
Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer.
Neoplasm Metastasis
Prolyl-4-hydroxylase ? subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.
Neoplasm Metastasis
Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.
Neoplasm Metastasis
Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model.
Neoplasm Metastasis
The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.
Neoplasm Metastasis
The Genes-Candidates for Prognostic Markers of Metastasis by Expression Level in Clear Cell Renal Cell Cancer.
Neoplasm Metastasis
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.
Neoplasm Metastasis
Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
Neoplasms
A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties.
Neoplasms
A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients.
Neoplasms
Abrogation of esophageal carcinoma development in miR-31 knockout rats.
Neoplasms
Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy.
Neoplasms
Apicidin upregulates PHD2 prolyl hydroxylase gene expression in cervical cancer cells.
Neoplasms
Aspirin targets P4HA2 through inhibiting NF-?B and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.
Neoplasms
Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate.
Neoplasms
Characterization of Glycolysis-Associated Molecules in the Tumor Microenvironment Revealed by Pan-Cancer Tissues and Lung Cancer Single Cell Data.
Neoplasms
Circ_101341 Deteriorates the Progression of Clear Cell Renal Cell Carcinoma Through the miR- 411/EGLN3 Axis.
Neoplasms
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1? stabilization and TNBC chemoresistance.
Neoplasms
Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer.
Neoplasms
Collagen prolyl 4-hydroxylases modify tumor progression.
Neoplasms
Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma.
Neoplasms
Collagen Type X Alpha 1 (COL10A1) Contributes to Cell Proliferation, Migration, and Invasion by Targeting Prolyl 4-Hydroxylase Beta Polypeptide (P4HB) in Breast Cancer.
Neoplasms
Defective p53 antiangiogenic signaling in glioblastoma.
Neoplasms
Differential protein expression in primary breast cancer and matched axillary node metastasis.
Neoplasms
EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability.
Neoplasms
Enzyme pathology of the liver in patients with and without nonhepatic cancer.
Neoplasms
Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma.
Neoplasms
Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer.
Neoplasms
Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma.
Neoplasms
Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumour cells in collagen type I synthesis.
Neoplasms
HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression.
Neoplasms
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Neoplasms
Homology modeling and molecular dynamics simulation of the HIF2? degradation-related HIF2?-VHL complex.
Neoplasms
Hypoxia-inducible factor prolyl-4-hydroxylase-1 is a convergent point in the reciprocal negative regulation of NF-?B and p53 signaling pathways.
Neoplasms
Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates With Immune Infiltration.
Neoplasms
Identification of P4HA1 as a prognostic biomarker for high-grade gliomas.
Neoplasms
Identification of Potential Diagnostic and Prognostic Values of P4HA1 Expression in Lung Cancer, Breast Cancer, and Head and Neck Cancer.
Neoplasms
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Neoplasms
Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts.
Neoplasms
Inactivation of HIF-prolyl 4-hydroxylases 1, 2 and 3 in NG2-expressing cells induces HIF2-mediated neurovascular expansion independent of erythropoietin.
Neoplasms
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.
Neoplasms
Induction of fibroblast-like cells from CD34(+) progenitor cells of the bone marrow in rheumatoid arthritis.
Neoplasms
Inhibition of Pancreatic Stellate Cell Activation by Halofuginone Prevents Pancreatic Xenograft Tumor Development.
Neoplasms
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Neoplasms
Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane.
Neoplasms
L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.
Neoplasms
Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer.
Neoplasms
LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer.
Neoplasms
MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA.
Neoplasms
Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment?
Neoplasms
Neuronal Apoptosis by Prolyl Hydroxylation: Implication in Nervous System Tumors and the Warburg Conundrum.
Neoplasms
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.
Neoplasms
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.
Neoplasms
Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Neoplasms
Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness.
Neoplasms
Overexpression of P4HA1 Is Correlated with Poor Survival and Immune Infiltrates in Lung Adenocarcinoma.
Neoplasms
Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma.
Neoplasms
Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors.
Neoplasms
P4HA1/HIF1? feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.
Neoplasms
P4HA2 contributes to cervical cancer progression via inducing epithelial-mesenchymal transition.
Neoplasms
P4HA2 Promotes Epithelial-to-Mesenchymal Transition and Glioma Malignancy through the Collagen-Dependent PI3K/AKT Pathway.
Neoplasms
P4HB: A novel diagnostic and prognostic biomarker for bladder carcinoma.
Neoplasms
Potential regulation of glioma through the induction of apoptosis signaling via Egl-9 family hypoxia-inducible factor 3.
Neoplasms
Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls.
Neoplasms
Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
Neoplasms
Prolyl-4-hydroxylase ? subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Neoplasms
Prolyl-4-Hydroxylase ? Subunit 2 as a Novel Potential Biomarker for Predicting the Prognosis of Epithelial Ovarian Carcinoma.
Neoplasms
Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.
Neoplasms
RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma.
Neoplasms
Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas.
Neoplasms
Suppression of glioma progression by egln3.
Neoplasms
Systematic Analysis of the Expression and Prognostic Significance of P4HA1 in Pancreatic Cancer and Construction of a lncRNA-miRNA-P4HA1 Regulatory Axis.
Neoplasms
Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder.
Neoplasms
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.
Neoplasms
Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model.
Neoplasms
Targeting the CBP/?-Catenin Interaction to Suppress Activation of Cancer-Promoting Pancreatic Stellate Cells.
Neoplasms
TGF-?-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers.
Neoplasms
The Choice of Candidates in Survival Markers Based on Coordinated Gene Expression in Renal Cancer.
Neoplasms
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.
Neoplasms
The contributions of HIF-target genes to tumor growth in RCC.
Neoplasms
The effect of lymphoma and other neoplasms on hepatic and plasma enzymes of the host rat.
Neoplasms
The kinesin KIF1B{beta} acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor.
Neoplasms
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.
Neoplasms
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Neoplasms
Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
Neoplasms
Tumor PHD2 expression is correlated with clinical features and prognosis of patients with HCC receiving liver resection.
Neoplasms
Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin.
Neoplasms
Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1.
Neoplasms
Two new mutations in the HIF2A gene associated with erythrocytosis.
Neoplasms
Update on mutations in the HIF: EPO pathway and their role in erythrocytosis.
Neoplasms
Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues.
Neoplasms
USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1B? via deubiquitinating EGLN3.
Nervous System Neoplasms
Neuronal Apoptosis by Prolyl Hydroxylation: Implication in Nervous System Tumors and the Warburg Conundrum.
Neurodegenerative Diseases
Proteome response to ochratoxin A-induced apoptotic cell death in mouse hippocampal HT22 cells.
Neurofibroma
Factor-XIIIa-positive cells in normal peripheral nerves and cutaneous neurofibromas of type-1 neurofibromatosis.
Non-alcoholic Fatty Liver Disease
HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD.
Non-alcoholic Fatty Liver Disease
Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Non-alcoholic Fatty Liver Disease.
Obesity
A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
Obesity
HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction.
Obesity
Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Obesity
Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance.
Obesity, Morbid
Hepatic collagen proline hydroxylase activity in hepatic disease following jejunoileal bypass for morbid obesity.
Osteoarthritis
Induction of fibroblast-like cells from CD34(+) progenitor cells of the bone marrow in rheumatoid arthritis.
Osteoarthritis
Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry.
Osteoarthritis
Regulation of type II collagen synthesis during osteoarthritis by prolyl-4-hydroxylases: possible influence of low oxygen levels.
Osteonecrosis
Hypoxia-inducible factor prolyl hydroxylase inhibitor prevents steroid-associated osteonecrosis of the femoral head in rabbits by promoting angiogenesis and inhibiting apoptosis.
Osteosarcoma
HIF in vascular development and tumour angiogenesis.
Osteosarcoma
Identification of a novel glycolysis-related gene signature for predicting the prognosis of osteosarcoma patients.
Osteosarcoma
Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts.
Ovarian Neoplasms
MiR-122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cells.
Ovarian Neoplasms
The plasma peptides of ovarian cancer.
Pancreatic Neoplasms
Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer.
Pancreatic Neoplasms
Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer.
Pancreatic Neoplasms
Systematic Analysis of the Expression and Prognostic Significance of P4HA1 in Pancreatic Cancer and Construction of a lncRNA-miRNA-P4HA1 Regulatory Axis.
Pancreatitis
Failure of a prolyl 4-hydroxylase inhibitor to alter extracellular matrix deposition during experimental pancreatitis.
Paraganglioma
PHD2 inactivation in Type I cells drives HIF-2?-dependent multilineage hyperplasia and the formation of paraganglioma-like carotid bodies.
Paraproteinemias
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.
Periodontitis
An injectable hydrogel-formulated inhibitor of prolyl-4-hydroxylase promotes T regulatory cell recruitment and enhances alveolar bone regeneration during resolution of experimental periodontitis.
Pheochromocytoma
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance.
Pheochromocytoma
Familial nonsyndromic pheochromocytoma.
Pheochromocytoma
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.
Polycythemia
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.
Polycythemia
A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove.
Polycythemia
Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis.
Polycythemia
Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.
Polycythemia
Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.
Polycythemia
HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques.
Polycythemia
Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.
Polycythemia
Notch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice.
Polycythemia
Oxygen sensing: recent insights from idiopathic erythrocytosis.
Pre-Eclampsia
Study on the Expressions of PHD and HIF in Placentas from Normal Pregnant Women and Patients with Preeclampsia.
Pre-Eclampsia
[Clinical significance of hypoxia inducible factor-prolyl hydroxylase 1 and factor inhibiting hypoxia inducible factor-1 expression in placentas of women with severe pre-eclampsia]
procollagen-proline 4-dioxygenase deficiency
Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection.
procollagen-proline 4-dioxygenase deficiency
Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis.
procollagen-proline 4-dioxygenase deficiency
Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.
procollagen-proline 4-dioxygenase deficiency
HIF-P4H-2 deficiency protects against skeletal muscle ischemia-reperfusion injury.
Prostatic Neoplasms
Identification of P4HA1 as a prognostic biomarker for high-grade gliomas.
Prostatic Neoplasms
MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer.
Prostatic Neoplasms
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.
Pulmonary Disease, Chronic Obstructive
Mining novel cell glycolysis related gene markers that can predict the survival of colon adenocarcinoma patients.
Pulmonary Disease, Chronic Obstructive
[The expression of hypoxia-inducible factor-1alpha and its hydroxylases in pulmonary arteries of patient with chronic obstructive pulmonary disease].
Pulmonary Fibrosis
Immunohistological detection of the beta subunit of prolyl 4-hydroxylase in rat and mini pig lungs with radiation-induced pulmonary fibrosis.
Pulmonary Fibrosis
Peplomycin sulfate and pulmonary fibrosis: hydroxyproline, uronic acid, proline hydroxylase and glucosamine 6-phosphate synthetase in lungs of hamsters treated with peplomycin.
Pulmonary Fibrosis
Protocollagen proline hydroxylase activity in experimental pulmonary fibrosis of rats.
Renal Insufficiency, Chronic
A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
Renal Insufficiency, Chronic
A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma.
Renal Insufficiency, Chronic
A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study.
Renal Insufficiency, Chronic
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Renal Insufficiency, Chronic
A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
Renal Insufficiency, Chronic
A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Renal Insufficiency, Chronic
Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
Renal Insufficiency, Chronic
Anemia management in dialysis patients: a PIVOT and a new path?
Renal Insufficiency, Chronic
Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways.
Renal Insufficiency, Chronic
Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
Renal Insufficiency, Chronic
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.
Renal Insufficiency, Chronic
Daprodustat: First Approval.
Renal Insufficiency, Chronic
Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Renal Insufficiency, Chronic
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Renal Insufficiency, Chronic
Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Renal Insufficiency, Chronic
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
Renal Insufficiency, Chronic
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
Renal Insufficiency, Chronic
Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Renal Insufficiency, Chronic
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Renal Insufficiency, Chronic
Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
Renal Insufficiency, Chronic
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Renal Insufficiency, Chronic
Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
Renal Insufficiency, Chronic
Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Renal Insufficiency, Chronic
Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
Renal Insufficiency, Chronic
Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
Renal Insufficiency, Chronic
Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Renal Insufficiency, Chronic
Erythropoietin regulates metabolic response in mice via receptor expression in adipose tissue, brain and bone.
Renal Insufficiency, Chronic
Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
Renal Insufficiency, Chronic
Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
Renal Insufficiency, Chronic
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
Renal Insufficiency, Chronic
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Renal Insufficiency, Chronic
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
Renal Insufficiency, Chronic
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
Renal Insufficiency, Chronic
In response to "Title: Letter to the Editor in response to the article 'Efficacy and safety of HIF prolyl hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis'".
Renal Insufficiency, Chronic
Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Renal Insufficiency, Chronic
Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Renal Insufficiency, Chronic
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Renal Insufficiency, Chronic
Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis.
Renal Insufficiency, Chronic
Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Renal Insufficiency, Chronic
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Renal Insufficiency, Chronic
Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.
Renal Insufficiency, Chronic
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Renal Insufficiency, Chronic
Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Renal Insufficiency, Chronic
Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
Renal Insufficiency, Chronic
Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
Renal Insufficiency, Chronic
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
Renal Insufficiency, Chronic
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
Renal Insufficiency, Chronic
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
Renal Insufficiency, Chronic
Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
Renal Insufficiency, Chronic
Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
Renal Insufficiency, Chronic
Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.
Renal Insufficiency, Chronic
[Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
Reperfusion Injury
HIF-P4H-2 deficiency protects against skeletal muscle ischemia-reperfusion injury.
Retinal Detachment
Prolyl-4-Hydroxylases Inhibitor Stabilizes HIF-1? and Increases Mitophagy to Reduce Cell Death After Experimental Retinal Detachment.
Retinal Diseases
Hypoxia-inducible factor expression in human RPE cells.
Retinal Neovascularization
REDUCED RETINAL NEOVASCULARIZATION, VASCULAR PERMEABILITY, AND APOPTOSIS IN ISCHEMIC RETINOPATHY IN THE ABSENCE OF PROLYL HYDROXYLASE-1 DUE TO THE PREVENTION OF HYPEROXIA-INDUCED VASCULAR OBLITERATION.
Sarcoma
Analysis of HIF-1alpha and its regulator, PHD2, in retroperitoneal sarcomas: Clinico-pathologic implications.
Sarcoma
Appearance of collagen proline hydroxylase in sera of mice with implanted sarcomas.
Sarcoma
Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts.
Schistosomiasis mansoni
Elevation of laminin and beta-subunit of prolyl 4-hydroxylase in the sera of human subjects with Schistosomiasis mansoni.
Scleroderma, Systemic
Cytokine regulation of prolyl 4-hydroxylase production in skin fibroblast cultures from patients with systemic sclerosis: contribution to collagen synthesis and fibrosis.
Scleroderma, Systemic
Effect of prolyl 4-hydroxylase inhibitor on fibroblast collagen production in vitro: an approach to the treatment of systemic sclerosis.
Scurvy
Collagen proline hydroxylase in wound healing, granuloma formation, scurvy, and growth.
Sleep Apnea, Obstructive
Prolyl 4-Hydroxylase Domain Protein 3-Inhibited Smooth-Muscle-Cell Dedifferentiation Improves Cardiac Perivascular Fibrosis Induced by Obstructive Sleep Apnea.
Spinal Cord Injuries
Hypoxia-inducible factor prolyl hydroxylase domain (PHD) inhibition after contusive spinal cord injury does not improve locomotor recovery.
Squamous Cell Carcinoma of Head and Neck
High P4HA1 expression is an independent prognostic factor for poor overall survival and recurrent-free survival in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Identification of PRDX4 and P4HA2 as Metastasis-Associated Proteins in Oral Cavity Squamous Cell Carcinoma by Comparative Tissue Proteomics of Microdissected Specimens Using iTRAQ Technology.
Squamous Cell Carcinoma of Head and Neck
Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness.
Squamous Cell Carcinoma of Head and Neck
P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Prognostic value of partial EMT-related genes in head and neck squamous cell carcinoma by a bioinformatic analysis.
Squamous Cell Carcinoma of Head and Neck
Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition.
Stomach Neoplasms
Collagen biosynthesis in gastric cancer: immunohistochemical analysis of prolyl 4-hydroxylase.
Stomach Neoplasms
Immunohistochemical study of collagen synthesis in an in-vitro model of scirrhous carcinoma of the stomach.
Stomach Neoplasms
LncRNA PCGEM1 enhances metastasis and gastric cancer invasion through targeting of miR-129-5p to regulate P4HA2 expression.
Stomach Neoplasms
P4HA3 is Epigenetically Activated by Slug in Gastric Cancer and its Deregulation is Associated With Enhanced Metastasis and Poor Survival.
Stomach Neoplasms
Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer.
Stomach Ulcer
Kinetics of fibroblasts in ulcer healing in rats: interference with indomethacin.
Stroke
Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?
Stroke
Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors.
Teratocarcinoma
An increase in prolyl-4-hydroxylase activity occurs during the retinoic acid-induced differentiation of mouse teratocarcinoma stem cell lines F9 and P19.
Teratoma
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.
Thyroid Neoplasms
Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumour cells in collagen type I synthesis.
Triple Negative Breast Neoplasms
Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers.
Tyrosinemias
Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.
Urinary Bladder Neck Obstruction
Collagen prolyl 4-hydroxylase is up-regulated in an acute bladder outlet obstruction.
Urinary Bladder Neck Obstruction
Effects of Prolyl 4-Hydroxylase Inhibitor on Bladder Function, Bladder Hypertrophy and Collagen Subtypes in a Rat Model With Partial Bladder Outlet Obstruction.
Urinary Bladder Neoplasms
Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder.
Uterine Cervical Neoplasms
Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer.
Uterine Cervical Neoplasms
Constructe a novel 5 hypoxia genes signature for cervical cancer.
Uterine Cervical Neoplasms
P4HA2 contributes to cervical cancer progression via inducing epithelial-mesenchymal transition.
Vasculitis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
von Hippel-Lindau Disease
Liver hypoxia and lack of recovery after reperfusion at high blood alcohol levels in the intragastric feeding model of alcohol liver disease.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Pihlajaniemi, T.; Helaakoski, T.; Tasanen, K.; Myllyl, R.; Huhtala, M.L.; Koivu, J.; Kivirikko, K.I.
Molecular cloning of the beta-subunit of human prolyl 4-hydroxylase. This subunit and protein disulfide isomerase are products of the same gene
EMBO J.
6
643-649
1987
Homo sapiens
brenda
Kivirikko, K.I.; Myllyl, R.
The hydroxylation of prolyl and lysyl residues
Enzymol. Post- transl. Modif. Proteins (Freedman, R. B. , Hawkins, H. C. , eds. ) Academic Press, New York
1
53-104
1980
Gallus gallus, Homo sapiens, Rattus norvegicus
-
brenda
Kivirikko, K.I.; Myllyl, R.
Posttranslational enzymes in the biosynthesis of collagen: intracellular enzymes
Methods Enzymol.
82
245-304
1982
Gallus gallus, Homo sapiens, Rattus norvegicus
brenda
Guzman, N.A.; Ascari, W.Q.; Cutroneo, K.R.; Desnick, R.J.
Comparison between avian and human prolyl 4-hydroxylases: studies on the holomeric enzymes and their constituent subunits
J. Cell. Biochem.
48
172-189
1992
Gallus gallus, Homo sapiens
brenda
Kivirikko, K.I.; Myllyl, R.; Pihlajaniemi, T.
Protein hydroxylation: prolyl 4-hydroxylase, an enzyme with four cosubstrates and a multifunctional subunit
FASEB J.
3
1609-1617
1989
Gallus gallus, Homo sapiens, Mus musculus, Volvox carteri
brenda
Gunzler, V.; Brocks, D.; Henke, S.; Myllyl, R.; Geiger, R.; Kivirikko, K.I.
Syncatalytic inactivation of prolyl 4-hydroxylase by synthetic peptides containing the unphysiologic amino acid 5-oxaproline
J. Biol. Chem.
263
19498-19504
1988
Gallus gallus, Homo sapiens
brenda
Gunzler, V.; Hanauske-Abel, H.M.; Myllyl, R.; Kaska, D.D.; Hanauske, A.; Kivirikko, K.I.
Syncatalytic inactivation of prolyl 4-hydroxylase by anthracyclines
Biochem. J.
251
365-372
1988
Gallus gallus, Homo sapiens
brenda
Gunzler, V.; Hanauske-Abel, H.M.; Myllyl, R.; Mohr, J.; Kivirikko, K.I.
Time-dependent inactivation of chick-embryo prolyl 4-hydroxylase by coumalic acid. Evidence for a syncatalytic mechanism
Biochem. J.
242
163-169
1987
Gallus gallus, Homo sapiens
brenda
Kivirikko, K.I.; Myllyl, R.
Recent developments in posttranslational modification: intracellular processing
Methods Enzymol.
144
96-114
1987
Gallus gallus, Homo sapiens, Mus musculus
brenda
Kuutti, L.R.; Tuderman, L.; Kivirikko, K.I.
Human prolyl hydroxylase. Purification, partial characterization and preparation of antiserum to the enzyme
Eur. J. Biochem.
57
181-188
1975
Homo sapiens
brenda
Helaakoski, T.; Vuori, K.; Myllyla, R.; Kivirikko, K.I.; Pihlajaniemi, T.
Molecular cloning of the a-subunit of human prolyl 4-hydroxylase: the complete cDNA-derived amino acid sequence and evidence for alternative splicing of RNA transcripts
Proc. Natl. Acad. Sci. USA
86
4392-4396
1989
Homo sapiens
brenda
Lamberg, A.; Pihlajaniemi, T.; Kivirikko, K.I.
Site-directed mutagenesis of the a subunit of human prolyl 4-hydroxylase. Identification of three histidine residues critical for catalytic activity
J. Biol. Chem.
270
9926-9931
1995
Homo sapiens
brenda
Helaakoski, T.; Annunen, P.; Vuori, K.; MacNeil, I.A.; Pihlajaniemi, T.; Kivirikko, K.I.
Cloning, baculovirus expression, and characterization of a second mouse prolyl 4-hydroxylase a-subunit isoform: formation of an a2b2 tetramer with the protein disulfide-isomerase/b subunit
Proc. Natl. Acad. Sci. USA
92
4427-4431
1995
Homo sapiens, Mus musculus
brenda
Mazzorana, M.; Snellman, A.; Kivirikko, K.I.; van der Rest, M.; Pihlajaniemi, T.
Involvement of prolyl 4-hydroxylase in the assembly of trimeric minicollagen XII. Study in baculovirus expression system
J. Biol. Chem.
271
29003-29008
1996
Homo sapiens
brenda
Annunen, P.; Helaakoski, T.; Myllyharju, J.; Veijola, J.; Pihlajaniemi, T.; Kivirikko, K.I.
Cloning of the human prolyl 4-hydroxylase a subunit isoform a(II) and characterization of the type II enzyme tetramer. The a(I) and a(II) subunits do not form a mixed a(I)a(II)b2 tetramer
J. Biol. Chem.
272
17342-17348
1997
Gallus gallus, Homo sapiens (O15460), Homo sapiens
brenda
Annunen, P.; Autio-Harmainen, H.; Kivirikko, K.I.
The novel type II prolyl 4-hydroxylase is the main enzyme form in chondrocytes and capillary endothelial cells, whereas the type I enzyme predominates in most cells
J. Biol. Chem.
273
5989-5992
1998
Homo sapiens, Mus musculus
brenda
Annunen, P.; Koivunen, P.; Kivirikko, K.I.
Cloning of the a subunit of prolyl 4-hydroxylase from Drosophila and expression and characterization of the corresponding enzyme tetramer with some unique properties
J. Biol. Chem.
274
6790-6796
1999
Drosophila melanogaster, Homo sapiens
brenda
Franklin, T.J.; Morris, W.P.; Edwards, P.N.; Large, M.S.; Stephenson, R.
Inhibition of prolyl 4-hydroxylase in vitro and in vivo by members of a novel series of phenanthrolinones
Biochem. J.
353
333-338
2001
Gallus gallus, Homo sapiens, Rattus norvegicus, Rattus norvegicus Sprague-Dawley
brenda
ekkala, M.; Hieta, R.; Kursula, P.; Kivirikko, K.I.; Wierenga, R.K.; Myllyharju, J.
Crystallization of the proline-rich-peptide binding domain of human type I collagen prolyl 4-hydroxylase
Acta Crystallogr. Sect. D
59
940-942
2003
Homo sapiens
brenda
Nissi, R.; Bohling, T.; Autio-Harmainen, H.
Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts
Acta Histochem.
106
111-121
2004
Homo sapiens, Rattus norvegicus
brenda
Tuckerman, J.R.; Zhao, Y.; Hewitson, K.S.; Tian, Y.M.; Pugh, C.W.; Ratcliffe, P.J.; Mole, D.R.
Determination and comparison of specific activity of the HIF-prolyl hydroxylases
FEBS Lett.
576
145-150
2004
Homo sapiens, Homo sapiens (Q96KS0), Homo sapiens (Q9H6Z9)
brenda
Hirsila, M.; Koivunen, P.; Gunzler, V.; Kivirikko, K.I.; Myllyharju, J.
Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor
J. Biol. Chem.
278
30772-30780
2003
Homo sapiens (Q96KS0), Homo sapiens (Q9GZT9), Homo sapiens (Q9H6Z9)
brenda
Hieta, R.; Kukkola, L.; Permi, P.; Pirilae, P.; Kivirikko, K.I.; Kilpelaeinen, I.; Myllyharju, J.
The peptide-substrate-binding domain of human collagen prolyl 4-hydroxylases: backbone assignments, secondary structure, and binding of proline-rich peptides
J. Biol. Chem.
278
34966-34974
2003
Homo sapiens
brenda
Kukkola, L.; Hieta, R.; Kivirikko, K.I.; Myllyharju, J.
Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme
J. Biol. Chem.
278
47685-47693
2003
Rattus norvegicus (Q6W3E9), Mus musculus (Q6W3F0), Mus musculus, Homo sapiens (Q7Z4N8), Homo sapiens
brenda
Myllyharju, J.
Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis
Matrix Biol.
22
15-24
2003
Arabidopsis thaliana, Drosophila melanogaster, Paramecium bursaria Chlorella virus-1, Homo sapiens (O15460), Homo sapiens (P13674), Caenorhabditis elegans (Q20065)
brenda
Kersteen, E.A.; Higgin, J.J.; Raines, R.T.
Production of human prolyl 4-hydroxylase in Escherichia coli
Protein Expr. Purif.
38
279-291
2004
Homo sapiens
brenda
Li, H.C.; Huang, C.C.; Chen, S.F.; Chou, M.Y.
Assembly of homotrimeric type XXI minicollagen by coexpression of prolyl 4-hydroxylase in stably transfected Drosophila melanogaster S2 cells
Biochem. Biophys. Res. Commun.
336
375-385
2005
Homo sapiens
brenda
Tian, Y.M.; Mole, D.R.; Ratcliffe, P.J.; Gleadle, J.M.
Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation
Biochem. J.
397
179-186
2006
Homo sapiens
brenda
Cervera, A.M.; Apostolova, N.; Luna-Crespo, F.; Sanjuan-Pla, A.; Garcia-Bou, R.; McCreath, K.J.
An alternatively spliced transcript of the PHD3 gene retains prolyl hydroxylase activity
Cancer Lett.
233
131-138
2006
Homo sapiens
brenda
Callapina, M.; Zhou, J.; Schnitzer, S.; Metzen, E.; Lohr, C.; Deitmer, J.W.; Bruene, B.
Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1alpha accumulation--implications for prolyl hydroxylase activity and iron
Exp. Cell Res.
306
274-284
2005
Homo sapiens
brenda
Chen, L.; Shen, Y.H.; Wang, X.; Wang, J.; Gan, Y.; Chen, N.; Wang, J.; LeMaire, S.A.; Coselli, J.S.; Wang, X.L.
Human prolyl-4-hydroxylase alpha(I) transcription is mediated by upstream stimulatory factors
J. Biol. Chem.
281
10849-10855
2006
Homo sapiens
brenda
Neubauer, A.; Soini, J.; Bollok, M.; Zenker, M.; Sandqvist, J.; Myllyharju, J.; Neubauer, P.
Fermentation process for tetrameric human collagen prolyl 4-hydroxylase in Escherichia coli: improvement by gene optimisation of the PDI/beta subunit and repeated addition of the inducer anhydrotetracycline
J. Biotechnol.
128
308-321
2007
Homo sapiens
brenda
Neubauer, A.; Neubauer, P.; Myllyharju, J.
High-level production of human collagen prolyl 4-hydroxylase in Escherichia coli
Matrix Biol.
24
59-68
2005
Homo sapiens
brenda
Choi, K.O.; Lee, T.; Lee, N.; Kim, J.H.; Yang, E.G.; Yoon, J.M.; Kim, J.H.; Lee, T.G.; Park, H.
Inhibition of the catalytic activity of hypoxia-inducible factor-1alpha-prolyl-hydroxylase 2 by a MYND-type zinc finger
Mol. Pharmacol.
68
1803-1809
2005
Homo sapiens
brenda
Cummins, E.P.; Berra, E.; Comerford, K.M.; Ginouves, A.; Fitzgerald, K.T.; Seeballuck, F.; Godson, C.; Nielsen, J.E.; Moynagh, P.; Pouyssegur, J.; Taylor, C.T.
Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity
Proc. Natl. Acad. Sci. USA
103
18154-18159
2006
Homo sapiens
brenda
McDonough, M.A.; Li, V.; Flashman, E.; Chowdhury, R.; Mohr, C.; Lienard, B.M.; Zondlo, J.; Oldham, N.J.; Clifton, I.J.; Lewis, J.; McNeill, L.A.; Kurzeja, R.J.; Hewitson, K.S.; Yang, E.; Jordan, S.; Syed, R.S.; Schofield, C.J.
Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)
Proc. Natl. Acad. Sci. USA
103
9814-9819
2006
Homo sapiens
brenda
Meng, L.; Huang, M.; Ye, X.; Fan, M.; Bian, Z.
Increased expression of collagen prolyl 4-hydroxylases in Chinese patients with hereditary gingival fibromatosis
Arch. Oral Biol.
52
1209-1214
2007
Homo sapiens
brenda
Villar, D.; Vara-Vega, A.; Landazuri, M.O.; Del Peso, L.
Identification of a region on hypoxia-inducible-factor prolyl 4-hydroxylases that determines their specificity for the oxygen degradation domains
Biochem. J.
408
231-240
2007
Homo sapiens (Q96KS0), Homo sapiens (Q9GZT9), Homo sapiens (Q9H6Z9)
brenda
Gorres, K.L.; Edupuganti, R.; Krow, G.R.; Raines, R.T.
Conformational preferences of substrates for human prolyl 4-hydroxylase
Biochemistry
47
9447-9455
2008
Homo sapiens
brenda
Zhang, C.; Zhang, M.; Shen, Y.H.; Burks, J.K.; Li, X.; LeMaire, S.A.; Yoshimura, K.; Aoki, H.; Matsuzaki, M.; An, F.; Engler, D.A.; Matsunami, R.K.; Coselli, J.S.; Zhang, Y.; Wang, X.L.
Role of NonO-histone interaction in TNFalpha-suppressed prolyl-4-hydroxylase alpha 1
Biochim. Biophys. Acta
1783
1517-1528
2008
Homo sapiens
brenda
Koivunen, P.; Tiainen, P.; Hyvaerinen, J.; Williams, K.E.; Sormunen, R.; Klaus, S.J.; Kivirikko, K.I.; Myllyharju, J.
An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha
J. Biol. Chem.
282
30544-30552
2007
Homo sapiens
brenda
Gorres, K.L.; Raines, R.T.
Direct and continuous assay for prolyl 4-hydroxylase
Anal. Biochem.
386
181-185
2009
Homo sapiens
brenda
Myllyharju, J.
Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets
Ann. Med.
40
402-417
2008
Caenorhabditis elegans, Chlamydomonas reinhardtii, Drosophila melanogaster, Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Stein, H.; Wilensky, M.; Tsafrir, Y.; Rosenthal, M.; Amir, R.; Avraham, T.; Ofir, K.; Dgany, O.; Yayon, A.; Shoseyov, O.
Production of bioactive, post-translationally modified, heterotrimeric, human recombinant type-I collagen in transgenic tobacco
Biomacromolecules
10
2640-2645
2009
Homo sapiens
brenda
Qi, H.H.; Ongusaha, P.P.; Myllyharju, J.; Cheng, D.; Pakkanen, O.; Shi, Y.; Lee, S.W.; Peng, J.; Shi, Y.
Prolyl 4-hydroxylation regulates Argonaute 2 stability
Nature
455
421-424
2008
Homo sapiens
brenda
Gorres, K.L.; Pua, K.H.; Raines, R.T.
Stringency of the 2-His-1-Asp active-site motif in prolyl 4-hydroxylase
PLoS ONE
4
e7635
2009
Homo sapiens
brenda
Chowdhury, R.; McDonough, M.A.; Mecinovic, J.; Loenarz, C.; Flashman, E.; Hewitson, K.S.; Domene, C.; Schofield, C.J.
Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases
Structure
17
981-989
2009
Homo sapiens
brenda
Xue, J.; Li, X.; Jiao, S.; Wei, Y.; Wu, G.; Fang, J.
Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity
Gastroenterology
138
606-615
2010
Homo sapiens
brenda
Vogel, S.; Wottawa, M.; Farhat, K.; Zieseniss, A.; Schnelle, M.; Le-Huu, S.; von Ahlen, M.; Malz, C.; Camenisch, G.; Katschinski, D.M.
Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation
J. Biol. Chem.
285
33756-33763
2010
Homo sapiens
brenda
Tennant, D.A.; Gottlieb, E.
HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression
J. Mol. Med.
88
839-849
2010
Homo sapiens
brenda
Spinella, F.; Rosano, L.; Del Duca, M.; Di Castro, V.; Nicotra, M.R.; Natali, P.G.; Bagnato, A.
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells
PLoS ONE
5
e11241
2010
Homo sapiens
brenda
Pektas, S.; Knapp, M.J.
Substrate preference of the HIF-prolyl hydroxylase-2 (PHD2) and substrate-induced conformational change
J. Inorg. Biochem.
126
55-60
2013
Homo sapiens
brenda
Yum, S.; Choi, J.; Hong, S.; Park, M.H.; Lee, J.; Ha, N.C.; Jung, Y.
Hyperoxia attenuates the inhibitory effect of nitric oxide donors on HIF prolyl-4-hydroxylase-2: Implication on discriminative effect of nitric oxide on HIF prolyl-4-hydroxylase-2 and collagen prolyl-4-hydroxylase
Biochem. Pharmacol.
82
485-490
2011
Homo sapiens
brenda
Vasta, J.D.; Higgin, J.J.; Kersteen, E.A.; Raines, R.T.
Bioavailable affinity label for collagen prolyl 4-hydroxylase
Bioorg. Med. Chem.
21
3597-3601
2013
Caenorhabditis elegans, Homo sapiens
brenda
Song, D.; Li, L.S.; Heaton-Johnson, K.J.; Arsenault, P.R.; Master, S.R.; Lee, F.S.
Prolyl hydroxylase domain protein 2 (PHD2) binds a Pro-Xaa-Leu-Glu motif, linking it to the heat shock protein 90 pathway
J. Biol. Chem.
288
9662-9674
2013
Homo sapiens
brenda
Duran, R.V.; MacKenzie, E.D.; Boulahbel, H.; Frezza, C.; Heiserich, L.; Tardito, S.; Bussolati, O.; Rocha, S.; Hall, M.N.; Gottlieb, E.
HIF-independent role of prolyl hydroxylases in the cellular response to amino acids
Oncogene
32
4549-4556
2013
Homo sapiens
brenda
Xiong, G.; Deng, L.; Zhu, J.; Rychahou, P.G.; Xu, R.
Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition
BMC Cancer
14
1-1
2014
Homo sapiens (O15460)
brenda
Liu, X.; Huang, X.; Chen, L.; Zhang, Y.; Li, M.; Wang, L.; Ge, C.; Wang, H.; Zhang, M.
Mechanical stretch promotes matrix metalloproteinase-2 and prolyl-4-hydroxylase alpha1 production in human aortic smooth muscle cells via Akt-p38 MAPK-JNK signaling
Int. J. Biochem. Cell Biol.
62
15-23
2015
Homo sapiens (P13674), Homo sapiens, Rattus norvegicus (P54001), Rattus norvegicus Wistar (P54001)
brenda
Timmins, A.; Saint-Andre, M.; de Visser, S.P.
Understanding how prolyl-4-hydroxylase structure steers a ferryl oxidant toward scission of a strong C-H bond
J. Am. Chem. Soc.
139
9855-9866
2017
Homo sapiens (P13674), Homo sapiens
brenda
Shi, R.; Gao, S.; Zhang, J.; Xu, J.; Graham, L.; Yang, X.; Li, C.
Collagen prolyl 4-hydroxylases modify tumor progression
Acta Biochim. Biophys. Sin. (Shanghai)
53
805-814
2021
Homo sapiens (O15460), Homo sapiens (P13674), Homo sapiens (Q7Z4N8)
brenda
Vasta, J.D.; Choudhary, A.; Jensen, K.H.; McGrath, N.A.; Raines, R.T.
Prolyl 4-hydroxylase substrate isosteres in which an (E)- or (Z)-alkene replaces the prolyl peptide bond
Biochemistry
56
219-227
2017
Chlamydomonas reinhardtii (A8IDI8), Chlamydomonas reinhardtii, Homo sapiens (P13674), Homo sapiens
brenda
Vasta, J.D.; Raines, R.T.
Collagen prolyl 4-hydroxylase as a therapeutic target
J. Med. Chem.
61
10403-10411
2018
Gallus gallus, Homo sapiens
brenda
Xiong, G.; Stewart, R.L.; Chen, J.; Gao, T.; Scott, T.L.; Samayoa, L.M.; OConnor, K.; Lane, A.N.; Xu, R.
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1alpha stabilization and TNBC chemoresistance
Nat. Commun.
9
4456
2018
Homo sapiens (P13674), Homo sapiens
brenda
Murthy, A.V.; Sulu, R.; Koski, M.K.; Tu, H.; Anantharajan, J.; Sah-Teli, S.K.; Myllyharju, J.; Wierenga, R.K.
Structural enzymology binding studies of the peptide-substrate-binding domain of human collagen prolyl 4-hydroxylase (type-II) High affinity peptides have a PxGP sequence motif
Protein Sci.
27
1692-1703
2018
Homo sapiens (O15460), Homo sapiens
brenda